CDKN2A and oropharyngeal carcinoma: Onita et al. [37] performed a retrospective review of patients with p16-positive oropharyngeal carcinomas who underwent, from 2006 to 2016, definitive radiotherapy concurrently with either triweekly cisplatin (n  =  251) or cetuximab (n  =  40).